Non-alcoholic fatty liver disease and liver transplantation

Metabolism: Clinical and Experimental

Volumn 65, Issue 8, 2016, Pages 1208-1223

  Khan, Reenam S ^a   Newsome, Philip N ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Liver transplantation; Metabolic syndrome; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; DECISION MAKING; DIABETES MELLITUS; FOLLOW UP; GRAFT SURVIVAL; GROUPS BY AGE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NONALCOHOLIC FATTY LIVER; OBESITY; ORGAN DONOR; OUTCOME ASSESSMENT; PATIENT MONITORING; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; TREATMENT INDICATION; CLINICAL DECISION MAKING; COMPLICATION; MORTALITY; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

CLINICAL DECISION-MAKING; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84961226571     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2016.02.013     Document Type: Article

References (177)

1. [1] Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L., Wymer, M., Global epidemiology of non-alcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence and outcomes. Hepatology, 2015.
2. [2] Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L.A., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40 (2008), 1461–1465.
3. [3] Day, C.P., Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver Int 26 (2006), 1021–1028.
4. [4] Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37 (2003), 917–923.
5. [5] Vernon, G., Baranova, A., Younossi, Z.M., Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34 (2011), 274–285.
6. [6] Williams, C.D., Stengel, J., Asike, M.I., Torres, D.M., Shaw, J., Contreras, M., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140 (2011), 124–131.
7. [7] Williams, R., Aspinall, R., Bellis, M., Camps-Walsh, G., Cramp, M., Dhawan, A., et al. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet 384 (2014), 1953–1997.
8. [8] Charlton, M.R., Burns, J.M., Pedersen, R.A., Watt, K.D., Heimbach, J.K., Dierkhising, R.A., Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 141 (2011), 1249–1253.
9. [9] Wong, R.J., Aguilar, M., Cheung, R., Perumpail, R.B., Harrison, S.A., Younossi, Z.M., et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 148 (2015), 547–555.
10. [10] Angulo, P., Kleiner, D.E., Dam-Larsen, S., Adams, L.A., Bjornsson, E.S., Charatcharoenwitthaya, P., et al. Liver fibrosis, but No other histologic features, Is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149 (2015), 389–397 [e10].
11. [11] Liou, I., Kowdley, K.V., Natural history of nonalcoholic steatohepatitis. J Clin Gastroenterol 40:Suppl. 1 (2006), S11–S16.
12. [12] NBa Transplant. Annual report on liver transplantation, 2014.
13. [13] Newsome, P.N., Allison, M.E., Andrews, P.A., Auzinger, G., Day, C.P., Ferguson, J.W., et al. Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis. Gut 61 (2012), 484–500.
14. [14] Grundy, S.M., Cleeman, J.I., Daniels, S.R., Donato, K.A., Eckel, R.H., Franklin, B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/national heart, lung, and blood institute scientific statement. Circulation 112 (2005), 2735–2752.
15. [15] Schwimmer, J.B., Pardee, P.E., Lavine, J.E., Blumkin, A.K., Cook, S., Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation 118 (2008), 277–283.
16. [16] Maurantonio, M., Ballestri, S., Odoardi, M.R., Lonardo, A., Loria, P., Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk?. Arch Med Res 42 (2011), 337–353.
17. [17] Bhatia, L.S., Curzen, N.P., Calder, P.C., Byrne, C.D., Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?. Eur Heart J 33 (2012), 1190–1200.
18. [18] Targher, G., Day, C.P., Bonora, E., Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363 (2010), 1341–1350.
19. [19] Rafiq, N., Bai, C., Fang, Y., Srishord, M., McCullough, A., Gramlich, T., et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 7 (2009), 234–238.
20. [20] Musso, G., Gambino, R., Cassader, M., Pagano, G., Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 43 (2011), 617–649.
21. [21] Ballestri, S., Lonardo, A., Bonapace, S., Byrne, C.D., Loria, P., Targher, G., Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol 20 (2014), 1724–1745.
22. [22] Villanova, N., Moscatiello, S., Ramilli, S., Bugianesi, E., Magalotti, D., Vanni, E., et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 42 (2005), 473–480.
23. [23] Akabame, S., Hamaguchi, M., Tomiyasu, K., Tanaka, M., Kobayashi-Takenaka, Y., Nakano, K., et al. Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography (MSCT). Circ J 72 (2008), 618–625.
24. [24] DeFilippis, A.P., Blaha, M.J., Martin, S.S., Reed, R.M., Jones, S.R., Nasir, K., et al. Nonalcoholic fatty liver disease and serum lipoproteins: the multi-ethnic study of atherosclerosis. Atherosclerosis 227 (2013), 429–436.
25. [25] Milani, A., Zaccaria, R., Bombardieri, G., Gasbarrini, A., Pola, P., Cirrhotic cardiomyopathy. Dig Liver Dis 39 (2007), 507–515.
26. [26] Wong, F., Girgrah, N., Graba, J., Allidina, Y., Liu, P., Blendis, L., The cardiac response to exercise in cirrhosis. Gut 49 (2001), 268–275.
27. [27] Adams, L.A., Lymp, J.F., St Sauver, J., Sanderson, S.O., Lindor, K.D., Feldstein, A., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 (2005), 113–121.
28. [28] Dunn, W., Xu, R., Wingard, D.L., Rogers, C., Angulo, P., Younossi, Z.M., et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 103 (2008), 2263–2271.
29. [29] Ong, J.P., Pitts, A., Younossi, Z.M., Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 49 (2008), 608–612.
30. [30] Ekstedt, M., Hagstrom, H., Nasr, P., Fredrikson, M., Stal, P., Kechagias, S., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61 (2015), 1547–1554.
31. [31] Maddur, H., Bourdillon, P.D., Liangpunsakul, S., Tector, A. Joseph, Fridell, J.A., Ghabril, M., et al. Role of cardiac catheterization and percutaneous coronary intervention in the preoperative assessment and management of patients before orthotopic liver transplantation. Liver Transpl 20 (2014), 664–672.
32. [32] Diedrich, D.A., Findlay, J.Y., Harrison, B.A., Rosen, C.B., Influence of coronary artery disease on outcomes after liver transplantation. Transplant Proc 40 (2008), 3554–3557.
33. [33] Hlatky, M.A., Boineau, R.E., Higginbotham, M.B., Lee, K.L., Mark, D.B., Califf, R.M., et al. A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status index). Am J Cardiol 64 (1989), 651–654.
34. [34] Smith, T.B., Stonell, C., Purkayastha, S., Paraskevas, P., Cardiopulmonary exercise testing as a risk assessment method in non cardio-pulmonary surgery: a systematic review. Anaesthesia 64 (2009), 883–893.
35. [35] Murray, K.F., Carithers, R.L., Jr. and Aasld. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 41 (2005), 1407–1432.
36. [36] Snipelisky, D., Levy, M., Shapiro, B., Utility of dobutamine stress echocardiography as part of the pre-liver transplant evaluation: an evaluation of its efficacy. Clin Cardiol 37 (2014), 468–472.
37. [37] Harinstein, M.E., Flaherty, J.D., Ansari, A.H., Robin, J., Davidson, C.J., Rossi, J.S., et al. Predictive value of dobutamine stress echocardiography for coronary artery disease detection in liver transplant candidates. Am J Transplant 8 (2008), 1523–1528.
38. [38] Davidson, C.J., Gheorghiade, M., Flaherty, J.D., Elliot, M.D., Reddy, S.P., Wang, N.C., et al. Predictive value of stress myocardial perfusion imaging in liver transplant candidates. Am J Cardiol 89 (2002), 359–360.
39. [39] Berman, D.S., Wong, N.D., Gransar, H., Miranda-Peats, R., Dahlbeck, J., Hayes, S.W., et al. Relationship between stress-induced myocardial ischemia and atherosclerosis measured by coronary calcium tomography. J Am Coll Cardiol 44 (2004), 923–930.
40. [40] Kemmer, N., Case, J., Chandna, S., Neff, G.W., The role of coronary calcium score in the risk assessment of liver transplant candidates. Transplant Proc 46 (2014), 230–233.
41. [41] Pletcher, M.J., Tice, J.A., Pignone, M., Browner, W.S., Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. Arch Intern Med 164 (2004), 1285–1292.
42. [42] Johnston, S.D., Morris, J.K., Cramb, R., Gunson, B.K., Neuberger, J., Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 73 (2002), 901–906.
43. [43] Guckelberger, O., Mutzke, F., Glanemann, M., Neumann, U.P., Jonas, S., Neuhaus, R., et al. Validation of cardiovascular risk scores in a liver transplant population. Liver Transpl 12 (2006), 394–401.
44. [44] Lee, T.H., Marcantonio, E.R., Mangione, C.M., Thomas, E.J., Polanczyk, C.A., Cook, E.F., et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 100 (1999), 1043–1049.
45. [45] Weber, M., Luchner, A., Seeberger, M., Mueller, C., Liebetrau, C., Schlitt, A., et al. Incremental value of high-sensitive troponin T in addition to the revised cardiac index for peri-operative risk stratification in non-cardiac surgery. Eur Heart J 34 (2013), 853–862.
46. [46] Dunkelgrun, M., Boersma, E., Schouten, O., Koopman-van Gemert, A.W., van Poorten, F., Bax, J.J., et al. Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE-IV). Ann Surg 249 (2009), 921–926.
47. [47] Mangano, D.T., Layug, E.L., Wallace, A., Tateo, I., Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. multicenter study of Perioperative Ischemia Research Group. N Engl J Med 335 (1996), 1713–1720.
48. [48] Tripathi, D., Hayes, P.C., The role of carvedilol in the management of portal hypertension. Eur J Gastroenterol Hepatol 22 (2010), 905–911.
49. [49] Banares, R., Moitinho, E., Matilla, A., Garcia-Pagan, J.C., Lampreave, J.L., Piera, C., et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology 36 (2002), 1367–1373.
50. [50] Serste, T., Melot, C., Francoz, C., Durand, F., Rautou, P.E., Valla, D., et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 52 (2010), 1017–1022.
51. [51] Grisham, J.W., A morphologic study of deoxyribonucleic acid synthesis and cell proliferation in regenerating rat liver; autoradiography with thymidine-H3. Cancer Res 22 (1962), 842–849.
52. [52] Ge, P.S., Runyon, B.A., The changing role of beta-blocker therapy in patients with cirrhosis. J Hepatol 60 (2014), 643–653.
53. [53] Hindler, K., Shaw, A.D., Samuels, J., Fulton, S., Collard, C.D., Riedel, B., Improved postoperative outcomes associated with preoperative statin therapy. Anesthesiology 105 (2006), 1260–1272 [quiz 89-90].
54. [54] Lindenauer, P.K., Pekow, P., Wang, K., Gutierrez, B., Benjamin, E.M., Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA 291 (2004), 2092–2099.
55. [55] Osamah, H., Mira, R., Sorina, S., Shlomo, K., Michael, A., Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. Br J Clin Pharmacol 44 (1997), 77–83.
56. [56] McKenney, J.M., Efficacy and safety of rosuvastatin in treatment of dyslipidemia. Am J Health Syst Pharm 62 (2005), 1033–1047.
57. [57] Yong, C.M., Sharma, M., Ochoa, V., Abnousi, F., Roberts, J., Bass, N.M., et al. Multivessel coronary artery disease predicts mortality, length of stay, and pressor requirements after liver transplantation. Liver Transpl 16 (2010), 1242–1248.
58. [58] Plotkin, J.S., Scott, V.L., Pinna, A., Dobsch, B.P., De Wolf, A.M., Kang, Y., Morbidity and mortality in patients with coronary artery disease undergoing orthotopic liver transplantation. Liver Transpl Surg 2 (1996), 426–430.
59. [59] Morris, J.J., Hellman, C.L., Gawey, B.J., Ramsay, M.A., Valek, T.R., Gunning, T.C., et al. Case 3-1995. three patients requiring both coronary artery bypass surgery and orthotopic liver transplantation. J Cardiothorac Vasc Anesth 9 (1995), 322–332.
60. [60] Lebbinck, H., Bouchez, S., Vereecke, H., Vanoverbeke, H., Troisi, R., Reyntjens, K., Sequential off-pump coronary artery bypass and liver transplantation. Transpl Int 19 (2006), 432–434.
61. [61] Kaplan, M., Cimen, S., Kut, M.S., Demirtas, M.M., Cardiac operations for patients with chronic liver disease. Heart Surg Forum 5 (2002), 60–65.
62. [62] Klemperer, J.D., Ko, W., Krieger, K.H., Connolly, M., Rosengart, T.K., Altorki, N.K., et al. Cardiac operations in patients with cirrhosis. Ann Thorac Surg 65 (1998), 85–87.
63. [63] Filsoufi, F., Rahmanian, P.B., Castillo, J.G., Chikwe, J., Carpentier, A., Adams, D.H., Early and late outcomes of cardiac surgery in patients with moderate to severe preoperative renal dysfunction without dialysis. Interact Cardiovasc Thorac Surg 7 (2008), 90–95.
64. [64] Azarbal, B., Poommipanit, P., Arbit, B., Hage, A., Patel, J., Kittleson, M., et al. Feasibility and safety of percutaneous coronary intervention in patients with end-stage liver disease referred for liver transplantation. Liver Transpl 17 (2011), 809–813.
65. [65] Sharma, M., Yong, C., Majure, D., Zellner, C., Roberts, J.P., Bass, N.M., et al. Safety of cardiac catheterization in patients with end-stage liver disease awaiting liver transplantation. Am J Cardiol 103 (2009), 742–746.
66. [66] Wiper, A., Schmitt, M., Roberts, D.H., Clopidogrel-induced hepatotoxicity. J Postgrad Med, 54, 2008, 152.
67. [67] Snipelisky, D.F., McRee, C., Seeger, K., Levy, M., Shapiro, B.P., Coronary interventions before liver transplantation might not avert postoperative cardiovascular events. Tex Heart Inst J 42 (2015), 438–442.
68. [68] Wray, C., Scovotti, J.C., Tobis, J., Niemann, C.U., Planinsic, R., Walia, A., et al. Liver transplantation outcome in patients with angiographically proven coronary artery disease: a multi-institutional study. Am J Transplant 13 (2013), 184–191.
69. [69] Torregrosa, M., Aguade, S., Dos, L., Segura, R., Gonzalez, A., Evangelista, A., et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 42 (2005), 68–74.
70. [70] Targher, G., Chonchol, M., Zoppini, G., Abaterusso, C., Bonora, E., Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link?. J Hepatol 54 (2011), 1020–1029.
71. [71] Houlihan, D.D., Armstrong, M.J., Davidov, Y., Hodson, J., Nightingale, P., Rowe, I.A., et al. Renal function in patients undergoing transplantation for nonalcoholic steatohepatitis cirrhosis: time to reconsider immunosuppression regimens?. Liver Transpl 17 (2011), 1292–1298.
72. [72] Fussner, L.A., Charlton, M.R., Heimbach, J.K., Fan, C., Dierkhising, R., Coss, E., et al. The impact of gender and NASH on chronic kidney disease before and after liver transplantation. Liver Int 34 (2014), 1259–1266.
73. [73] VanWagner, L.B., Lapin, B., Skaro, A.I., Lloyd-Jones, D.M., Rinella, M.E., Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Int, 2015.
74. [74] Weber, M.L., Ibrahim, H.N., Lake, J.R., Renal dysfunction in liver transplant recipients: evaluation of the critical issues. Liver Transpl 18 (2012), 1290–1301.
75. [75] Sherman, D.S., Fish, D.N., Teitelbaum, I., Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis 41 (2003), 269–278.
76. [76] Gonwa, T.A., McBride, M.A., Anderson, K., Mai, M.L., Wadei, H., Ahsan, N., Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us?. Am J Transplant 6 (2006), 2651–2659.
77. [77] Eason, J.D., Gonwa, T.A., Davis, C.L., Sung, R.S., Gerber, D., Bloom, R.D., Proceedings of consensus conference on simultaneous liver kidney transplantation (SLK). Am J Transplant 8 (2008), 2243–2251.
78. [78] Singal, A.K., Hasanin, M., Kaif, M., Wiesner, R., Kuo, Y.F., Nonalcoholic steatohepatitis is the most rapidly growing indication for simultaneous liver kidney transplantation in the United States. Transplantation 100:3 (2016), 607–612.
79. [79] Angulo, P., Nonalcoholic fatty liver disease. N Engl J Med 346 (2002), 1221–1231.
80. [80] Segev, D.L., Thompson, R.E., Locke, J.E., Simpkins, C.E., Thuluvath, P.J., Montgomery, R.A., et al. Prolonged waiting times for liver transplantation in obese patients. Ann Surg 248 (2008), 863–870.
81. [81] Dick, A.A., Perkins, J.D., Spitzer, A.L., Lao, O.B., Healey, P.J., Reyes, J.D., Impact of obesity on children undergoing liver transplantation. Liver Transpl 16 (2010), 1296–1302.
82. [82] LaMattina, J.C., Foley, D.P., Fernandez, L.A., Pirsch, J.D., Musat, A.I., D'Alessandro, A.M., et al. Complications associated with liver transplantation in the obese recipient. Clin Transpl 26 (2012), 910–918.
83. [83] Conzen, K.D., Vachharajani, N., Collins, K.M., Anderson, C.D., Lin, Y., Wellen, J.R., et al. Morbid obesity in liver transplant recipients adversely affects longterm graft and patient survival in a single-institution analysis. HPB (Oxford) 17 (2015), 251–257.
84. [84] Gunay, Y., Guler, N., Dayangac, M., Taskesen, F., Yaprak, O., Emek, E., et al. Living donor liver transplantation for obese patients: challenges and outcomes. Liver Transpl 20 (2014), 311–322.
85. [85] Tanaka, T., Sugawara, Y., Tamura, S., Kaneko, J., Takazawa, Y., Aoki, T., et al. Living donor liver transplantation for non-alcoholic steatohepatitis: a single center experience. Hepatol Res 44 (2014), E3–E10.
86. [86] Schunkert, H., Obesity and target organ damage: the heart. Int J Obes Relat Metab Disord 26:Suppl. 4 (2002), S15–S20.
87. [87] Leonard, J., Heimbach, J.K., Malinchoc, M., Watt, K., Charlton, M., The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database. Am J Transplant 8 (2008), 667–672.
88. [88] Stickel, F., Inderbitzin, D., Candinas, D., Role of nutrition in liver transplantation for end-stage chronic liver disease. Nutr Rev 66 (2008), 47–54.
89. [89] Carias, S., Castellanos, A.L., Vilchez, V., Nair, R., Dela Cruz, A., Watkins, J., et al. Non-alcoholic steatohepatitis is strongly associated with sarcopenic obesity in patients with cirrhosis undergoing liver transplant evaluation. J Gastroenterol Hepatol 31:3 (2016), 628–633.
90. [90] Nair, S., Verma, S., Thuluvath, P.J., Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 35 (2002), 105–109.
91. [91] Tanaka, T., Renner, E.L., Selzner, N., Therapondos, G., Lilly, L.B., The impact of obesity as determined by modified body mass index on long-term outcome after liver transplantation: Canadian single-center experience. Transplant Proc 45 (2013), 2288–2294.
92. [92] Orci, L.A., Majno, P.E., Berney, T., Morel, P., Mentha, G., Toso, C., The impact of wait list body mass index changes on the outcome after liver transplantation. Transpl Int 26 (2013), 170–176.
93. [93] Saab, S., Lalezari, D., Pruthi, P., Alper, T., Tong, M.J., The impact of obesity on patient survival in liver transplant recipients: a meta-analysis. Liver Int 35 (2015), 164–170.
94. [94] Al-Nowaylati, A.R., Al-Haddad, B.J., Dorman, R.B., Alsaied, O.A., Lake, J.R., Chinnakotla, S., et al. Gastric bypass after liver transplantation. Liver Transpl 19 (2013), 1324–1329.
95. [95] Himpens, J., Cadiere, G.B., Bazi, M., Vouche, M., Cadiere, B., Dapri, G., Long-term outcomes of laparoscopic adjustable gastric banding. Arch Surg 146 (2011), 802–807.
96. [96] Heimbach, J.K., Watt, K.D., Poterucha, J.J., Ziller, N.F., Cecco, S.D., Charlton, M.R., et al. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. Am J Transplant 13 (2013), 363–368.
97. [97] Lin, M.Y., Tavakol, M.M., Sarin, A., Amirkiai, S.M., Rogers, S.J., Carter, J.T., et al. Safety and feasibility of sleeve gastrectomy in morbidly obese patients following liver transplantation. Surg Endosc 27 (2013), 81–85.
98. [98] Duchini, A., Brunson, M.E., Roux-en-Y gastric bypass for recurrent nonalcoholic steatohepatitis in liver transplant recipients with morbid obesity. Transplantation 72 (2001), 156–159.
99. [99] Kemmer, N., Neff, G.W., Franco, E., Osman-Mohammed, H., Leone, J., Parkinson, E., et al. Nonalcoholic fatty liver disease epidemic and its implications for liver transplantation. Transplantation 96 (2013), 860–862.
100. [100] Abecassis, M., Bridges, N.D., Clancy, C.J., Dew, M.A., Eldadah, B., Englesbe, M.J., et al. Solid-organ transplantation in older adults: current status and future research. Am J Transplant 12 (2012), 2608–2622.
101. [101] Fontes, P., Lopez, R., van der Plaats, A., Vodovotz, Y., Minervini, M., Scott, V., et al. Liver preservation with machine perfusion and a newly developed cell-free oxygen carrier solution under subnormothermic conditions. Am J Transplant 15 (2015), 381–394.
102. [102] Samuelson, A.L., Lee, M., Kamal, A., Keeffe, E.B., Ahmed, A., Diabetes mellitus increases the risk of mortality following liver transplantation independent of MELD score. Dig Dis Sci 55 (2010), 2089–2094.
103. [103] Hoehn, R.S., Singhal, A., Wima, K., Sutton, J.M., Paterno, F., Woodle, E. Steve, et al. Effect of pretransplant diabetes on short-term outcomes after liver transplantation: a national cohort study. Liver Int 35 (2015), 1902–1909.
104. [104] Paramesh, A.S., Roayaie, S., Doan, Y., Schwartz, M.E., Emre, S., Fishbein, T., et al. Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease. Clin Transpl 18 (2004), 94–99.
105. [105] Moon, J.I., Barbeito, R., Faradji, R.N., Gaynor, J.J., Tzakis, A.G., Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: long-term follow up. Transplantation 82 (2006), 1625–1628.
106. [106] Shields, P.L., Tang, H., Neuberger, J.M., Gunson, B.K., McMaster, P., Pirenne, J., Poor outcome in patients with diabetes mellitus undergoing liver transplantation. Transplantation 68 (1999), 530–535.
107. [107] Park, C., Hsu, C., Neelakanta, G., Nourmand, H., Braunfeld, M., Wray, C., et al. Severe intraoperative hyperglycemia is independently associated with surgical site infection after liver transplantation. Transplantation 87 (2009), 1031–1036.
108. [108] Ammori, J.B., Sigakis, M., Englesbe, M.J., O'Reilly, M., Pelletier, S.J., Effect of intraoperative hyperglycemia during liver transplantation. J Surg Res 140 (2007), 227–233.
109. [109] Investigators, N.-S.S., Finfer, S., Chittock, D.R., Su, S.Y., Blair, D., Foster, D., et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 360 (2009), 1283–1297.
110. [110] Selzner, M., Rudiger, H.A., Sindram, D., Madden, J., Clavien, P.A., Mechanisms of ischemic injury are different in the steatotic and normal rat liver. Hepatology 32 (2000), 1280–1288.
111. [111] Selzner, M., Clavien, P.A., Failure of regeneration of the steatotic rat liver: disruption at two different levels in the regeneration pathway. Hepatology 31 (2000), 35–42.
112. [112] Farrell, G.C., Teoh, N.C., McCuskey, R.S., Hepatic microcirculation in fatty liver disease. Anat Rec 291 (2008), 684–692.
113. [113] Cho, J.Y., Suh, K.S., Lee, H.W., Cho, E.H., Yang, S.H., Cho, Y.B., et al. Hepatic steatosis is associated with intrahepatic cholestasis and transient hyperbilirubinemia during regeneration after living donor liver transplantation. Transpl Int 19 (2006), 807–813.
114. [114] Perkins, J.D., Saying “yes” to obese living liver donors: short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation. Liver Transpl 12 (2006), 1012–1013.
115. [115] Tevar, A.D., Clarke, C., Wang, J., Rudich, S.M., Woodle, E.S., Lentsch, A.B., et al. Clinical review of nonalcoholic steatohepatitis in liver surgery and transplantation. J Am Coll Surg 210 (2010), 515–526.
116. [116] D'Alessandro, A.M., Kalayoglu, M., Sollinger, H.W., Hoffmann, R.M., Reed, A., Knechtle, S.J., et al. The predictive value of donor liver biopsies on the development of primary nonfunction after orthotopic liver transplantation. Transplant Proc 23 (1991), 1536–1537.
117. [117] Wong, T.C., Fung, J.Y., Chok, K.S., Cheung, T.T., Chan, A.C., Sharr, W.W., et al. Excellent outcomes of liver transplantation using severely steatotic grafts from brain-dead donors. Liver Transpl, 2015.
118. [118] Verran, D., Kusyk, T., Painter, D., Fisher, J., Koorey, D., Strasser, S., et al. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transpl 9 (2003), 500–505.
119. [119] Graham, J.A., Guarrera, J.V., “resuscitation” of marginal liver allografts for transplantation with machine perfusion technology. J Hepatol 61 (2014), 418–431.
120. [120] Ravikumar, R., Tsochatzis, E., Jose, S., Allison, M., Athale, A., Creamer, F., et al. Risk factors for recurrent primary sclerosing cholangitis after liver transplantation. J Hepatol 63 (2015), 1139–1146.
121. [121] de Ledinghen, V., Vergniol, J., Foucher, J., Merrouche, W., le Bail, B., Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 32 (2012), 911–918.
122. [122] Singal, A.K., Guturu, P., Hmoud, B., Kuo, Y.F., Salameh, H., Wiesner, R.H., Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation 95 (2013), 755–760.
123. [123] Afzali, A., Berry, K., Ioannou, G.N., Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. Liver Transpl 18 (2012), 29–37.
124. [124] Yalamanchili, K., Saadeh, S., Klintmalm, G.B., Jennings, L.W., Davis, G.L., Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl 16 (2010), 431–439.
125. [125] Wang, X., Li, J., Riaz, D.R., Shi, G., Liu, C., Dai, Y., Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 12 (2014), 394–402 e1.
126. [126] Kennedy, C., Redden, D., Gray, S., Eckhoff, D., Massoud, O., McGuire, B., et al. Equivalent survival following liver transplantation in patients with non-alcoholic steatohepatitis compared with patients with other liver diseases. HPB (Oxford) 14 (2012), 625–634.
127. [127] Malik, S.M., ME deVera, P Fontes, O Shaikh and J Ahmad. outcome after liver transplantation for NASH cirrhosis. Am J Transplant 9 (2009), 782–793.
128. [128] Barritt, ASt, Dellon, E.S., Kozlowski, T., Gerber, D.A., Hayashi, P.H., The influence of nonalcoholic fatty liver disease and its associated comorbidities on liver transplant outcomes. J Clin Gastroenterol 45 (2011), 372–378.
129. [129] Vanwagner, L.B., Bhave, M., Te, H.S., Feinglass, J., Alvarez, L., Rinella, M.E., Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. Hepatology 56 (2012), 1741–1750.
130. [130] Working, G. Banff, Demetris, A.J., Adeyi, O., Bellamy, C.O., Clouston, A., Charlotte, F., et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 44 (2006), 489–501.
131. [131] Bhagat, V., Mindikoglu, A.L., Nudo, C.G., Schiff, E.R., Tzakis, A., Regev, A., Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. Liver Transpl 15 (2009), 1814–1820.
132. [132] Contos, M.J., Cales, W., Sterling, R.K., Luketic, V.A., Shiffman, M.L., Mills, A.S., et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 7 (2001), 363–373.
133. [133] Charlton, M., Kasparova, P., Weston, S., Lindor, K., Maor-Kendler, Y., Wiesner, R.H., et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 7 (2001), 608–614.
134. [134] Dureja, P., Mellinger, J., Agni, R., Chang, F., Avey, G., Lucey, M., et al. NAFLD recurrence in liver transplant recipients. Transplantation 91 (2011), 684–689.
135. [135] El Atrache, M.M., Abouljoud, M.S., Divine, G., Yoshida, A., Kim, D.Y., Kazimi, M.M., et al. Recurrence of non-alcoholic steatohepatitis and cryptogenic cirrhosis following orthotopic liver transplantation in the context of the metabolic syndrome. Clin Transpl 26 (2012), E505–E512.
136. [136] Vallin, M., Guillaud, O., Boillot, O., Hervieu, V., Scoazec, J.Y., Dumortier, J., Recurrent or de novo nonalcoholic fatty liver disease after liver transplantation: natural history based on liver biopsy analysis. Liver Transpl 20 (2014), 1064–1071.
137. [137] Finkenstedt, A., Auer, C., Glodny, B., Posch, U., Steitzer, H., Lanzer, G., et al. Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis. Clin Gastroenterol Hepatol 11 (2013), 1667–1672.
138. [138] Burke, A., Lucey, M.R., Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation. Am J Transplant 4 (2004), 686–693.
139. [139] Seo, S., Maganti, K., Khehra, M., Ramsamooj, R., Tsodikov, A., Bowlus, C., et al. De novo nonalcoholic fatty liver disease after liver transplantation. Liver Transpl 13 (2007), 844–847.
140. [140] Testino, G., Sumberaz, A., Leone, S., Borro, P., Recurrent hepatitis C and non-alcoholic fatty liver disease in transplanted patients: a review. Minerva Med 104 (2013), 225–232.
141. [141] Sprinzl, M.F., Weinmann, A., Lohse, N., Tonissen, H., Koch, S., Schattenberg, J., et al. Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation. Transpl Int 26 (2013), 67–74.
142. [142] Dumortier, J., Giostra, E., Belbouab, S., Morard, I., Guillaud, O., Spahr, L., et al. Non-alcoholic fatty liver disease in liver transplant recipients: another story of "seed and soil". Am J Gastroenterol 105 (2010), 613–620.
143. [143] Kim, H., Lee, K., Lee, K.W., Yi, N.J., Lee, H.W., Hong, G., et al. Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation. Clin Transpl 28 (2014), 521–529.
144. [144] Watt, K.D., Charlton, M.R., Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol 53 (2010), 199–206.
145. [145] Laish, I., Braun, M., Mor, E., Sulkes, J., Harif, Y., Ari, Z. Ben, Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. Liver Transpl 17 (2011), 15–22.
146. [146] Sheiner, P.A., Magliocca, J.F., Bodian, C.A., Kim-Schluger, L., Altaca, G., Guarrera, J.V., et al. Long-term medical complications in patients surviving > or = 5 years after liver transplant. Transplantation 69 (2000), 781–789.
147. [147] Stegall, M.D., Everson, G., Schroter, G., Bilir, B., Karrer, F., Kam, I., Metabolic complications after liver transplantation. diabetes, hypercholesterolemia, hypertension, and obesity. Transplantation 60 (1995), 1057–1060.
148. [148] Bianchi, G., Marchesini, G., Marzocchi, R., Pinna, A.D., Zoli, M., Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl 14 (2008), 1648–1654.
149. [149] Ojo, A.O., Held, P.J., Port, F.K., Wolfe, R.A., Leichtman, A.B., Young, E.W., et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349 (2003), 931–940.
150. [150] Tueche, S.G., Diabetes mellitus after liver transplant new etiologic clues and cornerstones for understanding. Transplant Proc 35 (2003), 1466–1468.
151. [151] McAlister, V.C., Haddad, E., Renouf, E., Malthaner, R.A., Kjaer, M.S., Gluud, L.L., Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 6 (2006), 1578–1585.
152. [152] Haddad, E.M., McAlister, V.C., Renouf, E., Malthaner, R., Kjaer, M.S., Gluud, L.L., Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev, 2006, CD005161.
153. [153] Watt, K.D., Dierkhising, R., Fan, C., Heimbach, J.K., Tillman, H., Goldstein, D., et al. Investigation of PNPLA3 and IL28B genotypes on diabetes and obesity after liver transplantation: insight into mechanisms of disease. Am J Transplant 13 (2013), 2450–2457.
154. [154] Veldt, B.J., Duarte-Rojo, A., Thompson, A.J., Watt, K.D., Heimbach, J.K., Tillmann, H.L., et al. Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C. Am J Transplant 12 (2012), 737–744.
155. [155] Charlton, M., Evolving aspects of liver transplantation for nonalcoholic steatohepatitis. Curr Opin Ophthalmol 18 (2013), 251–258.
156. [156] Kim, W.R., Poterucha, J.J., Porayko, M.K., Dickson, E.R., Steers, J.L., Wiesner, R.H., Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 62 (1996), 1802–1805.
157. [157] Pruthi, J., Medkiff, K.A., Esrason, K.T., Donovan, J.A., Yoshida, E.M., Erb, S.R., et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 7 (2001), 811–815.
158. [158] Segev, D.L., Sozio, S.M., Shin, E.J., Nazarian, S.M., Nathan, H., Thuluvath, P.J., et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl 14 (2008), 512–525.
159. [159] Farkas, S.A., Schnitzbauer, A.A., Kirchner, G., Obed, A., Banas, B., Schlitt, H.J., Calcineurin inhibitor minimization protocols in liver transplantation. Transpl Int 22 (2009), 49–60.
160. [160] O'Grady, J.G., Burroughs, A., Hardy, P., Elbourne, D., Truesdale, A., Uk, et al. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet 360 (2002), 1119–1125.
161. [161] Reich, D.J., Clavien, P.A., Hodge, E.E., MMFRDaLTW Group, Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. Transplantation 80 (2005), 18–25.
162. [162] Mofrad, P., Contos, M.J., Haque, M., Sargeant, C., Fisher, R.A., Luketic, V.A., et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37 (2003), 1286–1292.
163. [163] Saadeh, S., Younossi, Z.M., Remer, E.M., Gramlich, T., Ong, J.P., Hurley, M., et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123 (2002), 745–750.
164. [164] Kaser, S., Moschen, A., Cayon, A., Kaser, A., Crespo, J., Pons-Romero, F., et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 54 (2005), 117–121.
165. [165] Dehghani, S.M., Taghavi, S.A., Eshraghian, A., Gholami, S., Imanieh, M.H., Bordbar, M.R., et al. Hyperlipidemia in Iranian liver transplant recipients: prevalence and risk factors. J Gastroenterol 42 (2007), 769–774.
166. [166] Perez-Protto, S.E., Quintini, C., Reynolds, L.F., You, J., Cywinski, J.B., Sessler, D.I., et al. Comparable graft and patient survival in lean and obese liver transplant recipients. Liver Transpl 19 (2013), 907–915.
167. [167] Dare, A.J., Plank, L.D., Phillips, A.R., Gane, E.J., Harrison, B., Orr, D., et al. Additive effect of pretransplant obesity, diabetes, and cardiovascular risk factors on outcomes after liver transplantation. Liver Transpl 20 (2014), 281–290.
168. [168] Singhal, A., Wilson, G.C., Wima, K., Quillin, R.C., Cuffy, M., Anwar, N., et al. Impact of recipient morbid obesity on outcomes after liver transplantation. Transpl Int 28 (2015), 148–155.
169. [169] Schaeffer, D.F., Yoshida, E.M., Buczkowski, A.K., Chung, S.W., Steinbrecher, U.P., Erb, S.E., et al. Surgical morbidity in severely obese liver transplant recipients - a single Canadian Centre experience. Ann Hepatol 8 (2009), 38–40.
170. [170] Hakeem, A.R., Cockbain, A.J., Raza, S.S., Pollard, S.G., Toogood, G.J., Attia, M.A., et al. Increased morbidity in overweight and obese liver transplant recipients: a single-center experience of 1325 patients from the United Kingdom. Liver Transpl 19 (2013), 551–562.
171. [171] Werneck, M., Afonso, R.C., Coelho, G.R., Sboarini, C., Coelho, M.P., Thome, T., et al. Obese and nonobese recipients had similar need for ventilatory support after liver transplantation. Transplant Proc 43 (2011), 165–169.
172. [172] Dick, A.A., Spitzer, A.L., Seifert, C.F., Deckert, A., Carithers, R.L. Jr., Reyes, J.D., et al. Liver transplantation at the extremes of the body mass index. Liver Transpl 15 (2009), 968–977.
173. [173] Boin, I.F., Almeida, L.V., Udo, E.Y., Stucchi, R.S., Cardoso, A.R., Caruy, C.A., et al. Survival analysis of obese patients undergoing liver transplantation. Transplant Proc 39 (2007), 3225–3227.
174. [174] Fujikawa, T., Fujita, S., Mizuno, S., Shenkman, E., Vogel, B., Lipori, P., et al. Clinical and financial impact of obesity on the outcome of liver transplantation. Transplant Proc 38 (2006), 3612–3614.
175. [175] Hillingso, J.G., Wettergren, A., Hyoudo, M., Kirkegaard, P., Obesity increases mortality in liver transplantation–the Danish experience. Transpl Int 18 (2005), 1231–1235.
176. [176] Sawyer, R.G., Pelletier, S.J., Pruett, T.L., Increased early morbidity and mortality with acceptable long-term function in severely obese patients undergoing liver transplantation. Clin Transpl 13 (1999), 126–130.
177. [177] Braunfeld, M.Y., Chan, S., Pregler, J., Neelakanta, G., Sopher, M.J., Busuttil, R.W., et al. Liver transplantation in the morbidly obese. J Clin Anesth 8 (1996), 585–590.